首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants
【2h】

Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants

机译:LDLr活性作为改善家族性高胆固醇血症遗传诊断的工具的验证:LDLr变体功能表征的回顾

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by high blood-cholesterol levels mostly caused by mutations in the low-density lipoprotein receptor (LDLr). With a prevalence as high as 1/200 in some populations, genetic screening for pathogenic LDLr mutations is a cost-effective approach in families classified as ‘definite’ or ‘probable’ FH and can help to early diagnosis. However, with over 2000 LDLr variants identified, distinguishing pathogenic mutations from benign mutations is a long-standing challenge in the field. In 1998, the World Health Organization (WHO) highlighted the importance of improving the diagnosis and prognosis of FH patients thus, identifying LDLr pathogenic variants is a longstanding challenge to provide an accurate genetic diagnosis and personalized treatments. In recent years, accessible methodologies have been developed to assess LDLr activity in vitro, providing experimental reproducibility between laboratories all over the world that ensures rigorous analysis of all functional studies. In this review we present a broad spectrum of functionally characterized missense LDLr variants identified in patients with FH, which is mandatory for a definite diagnosis of FH.
机译:家族性高胆固醇血症(FH)是常染色体显性遗传疾病,其特征在于高胆固醇水平主要是由低密度脂蛋白受体(LDLr)的突变引起的。在某些人群中,致病性LDLr突变的患病率高达1/200,对于分类为“确定的”或“可能的” FH的家庭,这是一种经济有效的方法,可以帮助早期诊断。然而,在鉴定出超过2000个LDLr变体后,将病原性突变与良性突变区分开是该领域的长期挑战。 1998年,世界卫生组织(WHO)强调了改善FH患者的诊断和预后的重要性,因此,鉴定LDLr致病变异是提供准确的遗传诊断和个性化治疗的长期挑战。近年来,已经开发出可访问的方法来评估体外LDLr活性,从而在世界各地的实验室之间提供实验可重复性,从而确保对所有功能研究进行严格的分析。在这篇综述中,我们介绍了在FH患者中鉴定的功能特征广泛的错义LDLr变体,这对于FH的明确诊断是必不可少的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号